Danish firm Galecto Biotech AB is readying its inhaled treatment for idiopathic pulmonary fibrosis (IPF), TD139, a selective inhibitor of galectin-3, for international Phase II/III trials.
TD139 is a specific inhibitor of the galactoside binding pocket of galectin-3. It has been formulated for inhalation to enable...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?